35 results
S-3ASR
IMCR
Immunocore Holdings plc
20 Mar 24
Automatic shelf registration
8:51pm
to the year of disposition or “excess distribution” cannot be offset by any net operating losses for such years, and gains (but not losses) realized
10-K
2023 FY
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
the acquisition or even to offset the associated acquisition and maintenance costs.
Depending on the size and nature of future strategic acquisitions … of active income to offset our passive financing income. Therefore, we cannot give any assurance regarding our PFIC status for the current or any future
6-K
EX-99.2
IMCR
Immunocore Holdings plc
7 Nov 23
Current report (foreign)
7:09am
to which we can benefit from U.K. research and development tax relief.
Un-surrendered U.K. tax losses are carried forward indefinitely to be offset … with our preclinical and other research expenses, driven primarily by our other pre-IND programs. These increases were partially offset by a decrease
6-K
EX-99.2
IMCR
Immunocore Holdings plc
10 Aug 23
Current report (foreign)
8:28am
losses are carried forward indefinitely to be offset against future taxable profits, subject to any relevant utilization criteria and restrictions … preclinical candidates, driven primarily by our three pre-IND programs. These increases were partially offset by a decrease of £1.9 million of costs under our
6-K
EX-99.2
IMCR
Immunocore Holdings plc
10 May 23
Current report (foreign)
7:27am
losses are carried forward to be offset against future taxable profits. After accounting for tax credits receivable, there were accumulated tax losses … the exercise of share options of £5.0 million and £0.3 million in the three months ended March 31, 2023 and 2022, respectively, partially offset by payments made
6-K/A
EX-99.1
08jz7tloxu4lc80ye5i
18 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
4:17pm
6-K
EX-99.2
6rx0n8
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
EX-99.1
gc6nitxzdlb8qpqsbp
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
424B5
uysidg2 52
9 Sep 22
Prospectus supplement for primary offering
4:23pm
6-K
EX-99.1
qktoc88kxj
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
6-K
EX-99.2
0d0zhzm
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
6-K
EX-99.1
eyiitpkekc83dzezixfd
11 May 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:08am
6-K
EX-99.2
3ruxv2ushyw
11 May 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:08am
6-K
EX-99.1
c924c
3 Mar 22
Immunocore Reports Full Year 2021 Financial Results
7:01am
6-K
EX-99.2
nluso3 evl7gy
10 Nov 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:01am
6-K
EX-99.2
lvhmtd 2ija6t9
11 Aug 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:00am
6-K
EX-99.2
13oiwd9t5ky7udo307
12 May 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:00am
20-F
tk4y80837 inct12kw2
25 Mar 21
Annual report (foreign)
7:01am
424B4
qn6tc0 mg03f
8 Feb 21
Prospectus supplement with pricing info
8:36am